Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00325156|
Recruitment Status : Completed
First Posted : May 12, 2006
Results First Posted : February 7, 2017
Last Update Posted : January 2, 2020
To assess the safety and reactogenicity of the DTPa-IPV/Hib vaccine as primary and booster vaccination. The DTPa-IPV/Hib vaccine given at 3 and 4 months of age is co-administered with GSK Biologicals' rotavirus vaccine or Placebo.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
|Condition or disease||Intervention/treatment||Phase|
|Diphtheria Tetanus Poliomyelitis Acellular Pertussis Haemophilus Influenzae Type b Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines||Biological: GSK Biologicals' combined DTPa-IPV/Hib vaccine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2590 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants.|
|Actual Study Start Date :||November 2, 2004|
|Actual Primary Completion Date :||August 23, 2007|
|Actual Study Completion Date :||August 23, 2007|
|Experimental: Group A||
Biological: GSK Biologicals' combined DTPa-IPV/Hib vaccine
4 intramuscular injections
- Number of Subjects Reporting Any Solicited Local and General Symptoms [ Time Frame: During the 4-day (Days 0-3) post-vaccination period, across doses ]Assessed solicited local and general symptoms were pain, redness, swelling, drowsiness, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C )], irritability and loss of appetite. Any was defined as any report of the specified symptom irrespective of intensity grade and relationship to vaccination.
- Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) [ Time Frame: During the 30-day (Days 0-29) post-vaccination period ]An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
- Number of Subjects Reporting Large Injection Site Swelling [ Time Frame: At Month 18, post-booster dose ]A large swelling reaction was defined as swelling with a diameter greater than (>) 50 millimeters (mm), noticeable diffuse swelling or noticeable increase of limb circumference.
- Number of Subjects Reporting Any Serious Adverse Events (SAEs) [ Time Frame: During the entire study period ]Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00325156
|GSK Investigational Site|
|Singapore, Singapore, 308433|
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|